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Abstract
Aims/hypothesis Women with type 1 or type 2 diabetes are at
increased risk of pre-eclampsia. Overweight and obesity are
associated with an increased risk of pre-eclampsia in women
without diabetes. The aim of the study was to investigate the
impact of maternal overweight and obesity on the risk of pre-
eclampsia in women with type 1 diabetes or type 2 diabetes.
Methods In a population-based cohort study including single-
ton births in Sweden, we estimated the risk of pre-eclampsia
among women with type 1 diabetes (n=7062) and type 2 dia-
betes (n=886), and investigated whether maternal overweight
(BMI 25–29.9 kg/m2) and obesity (BMI ≥30.0 kg/m2) modi-
fied the risk. Logistic regression analyses were used to estimate
crude and adjusted ORs with 95% CIs, using women without
diabetes as the reference group (n=1,509,525).
Results Compared with women without diabetes, the adjusted
ORs for pre-eclampsia in women with type 1 and type 2 diabetes
were 5.74 (95% CI 5.31, 6.20) and 2.11 (95% CI 1.65, 2.70),
respectively. The corresponding risks of pre-eclampsia combined
with preterm birth were even higher. Risks of pre-eclampsia
increased with maternal overweight (BMI 25–29.9 kg/m2) and
obesity (BMI ≥30.0 kg/m2), foremost in women without
diabetes, to a lesser extent in women with type 1 diabetes but
not in women with type 2 diabetes.
Conclusions/interpretation Maternal overweight and obesity
increased risks of pre-eclampsia in women with type 1 diabe-
tes but not in women with type 2 diabetes. Even so, consider-
ing associations between maternal BMI and overall maternal
and offspring risk, all women (with and without diabetes)
should aim for a normal weight before pregnancy.
Keywords BMI .Diabetes type1 .Diabetes type2 .Moderate
pre-eclampsia .Obesity .Overweight .Pre-eclampsia .Riskof
pre-eclampsia . Severe pre-eclampsia
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Introduction
The outcome of pregnancies complicated by pregestational
diabetes has markedly improved over the last few decades.
However, the risk of severe maternal complications is still
considerably increased [1, 2], including a 2–6 times higher
risk of pre-eclampsia compared with women without diabetes
[3]. Pre-eclampsia accounts for more than half of all maternal
deaths per year in high income countries [4], and is associated
with substantially increased risks of stillbirth, preterm birth
and infant mortality [5, 6]. Effective predictors for its early
detection are lacking [7] and delivery is the only cure for pre-
eclampsia.
In women with type 1 diabetes, a number of risk factors for
pre-eclampsia have been identified [8]. The most salient in-
clude elevated first trimester HbA1c and both incipient and
overt nephropathy [9, 10]. Risk factors for pre-eclampsia in
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women with type 2 diabetes are less well studied [11].
However, the prevalence of overweight and obesity continues
to rise in general [12], also in women with type 1 or type 2
diabetes [13, 14].
In women without diabetes, high BMI is an important risk
factor for both moderate and severe pre-eclampsia [15, 16].
We previously demonstrated that maternal overweight and
obesity increase the risk of pre-eclampsia in women with type
1 diabetes [17]. However, we are unaware of studies focusing
on associations between maternal overweight and obesity and
the risk of pre-eclampsia in women with type 2 diabetes.
Therefore, the aim of the current study was to compare the
impact of maternal BMI on pre-eclampsia risks in women
with type 1 and type 2 diabetes. We also wanted to explore
the effect of maternal overweight and obesity on risks of pre-
eclampsia subtypes, including moderate and severe pre-
eclampsia, and pre-eclampsia leading to preterm birth.
Methods
Study design and study population The national Swedish
Medical Birth Register (MBR) contains data on more than
98% of all births in Sweden. Between 1997 and 2012, the
MBR added information on 1,600,575 births. We excluded
mothers with missing personal identification numbers
(n= 19,001) and with no information on country of birth
(n=1108). We also excluded multiple births (n=46,662) and
births with unknown gestational age (n=1122). In order to
compare the risks of pre-eclampsia in women with type 1
and type 2 diabetes and women without diabetes, we also
excluded women with gestational diabetes (n = 15,209).
Thus, the final study population comprised 1,517,473 women
with singleton births.
The Swedish MBR is subject to quality control by the
National Board of Health and Welfare, and the coverage
and validity of most variables are considered to be high
[18]. Information on maternal sociodemographic factors, an-
thropometry, medical history, and obstetric and perinatal out-
come is recorded prospectively by midwifes and physicians
using standardised forms during pregnancy, delivery and the
neonatal period. Maternal and neonatal diagnoses are classi-
fied by the physician according the International
Classification of Diseases; ICD-10 has been used since
1997. We used the personal identification number [19]
assigned to all citizens in Sweden to cross-link data from
the MBR to the Total Population Register for the maternal
country of birth and to the Education Register for the
mother’s highest attained level of education [20, 21].
Ethical approval was obtained from the Research Ethics
Committee of the Karolinska Institutet, Stockholm, Sweden
(no. 2012/1813-31/4).
Exposures The main exposures were maternal type 1 and
type 2 diabetes, and maternal BMI. Identification of women
with type 1 or type 2 diabetes was based on ICD-10 codes
O240 and O241, respectively. The reference group com-
prised women without gestational diabetes or type 1 or type
2 diabetes. Maternal BMI (kg/m2) was calculated from
weight measured wearing light indoor clothing and self-
reported height at the first antenatal visit, usually during
the first trimester [18]. Women were categorised according
to the WHO criteria as underweight (BMI <18.5 kg/m2),
normal weight (BMI 18.5–24.9 kg/m2), overweight (BMI
25–29.9 kg/m2) or obese (BMI ≥30 kg/m2) [22].
Covariates Information on maternal height, age at delivery,
parity and self-reported smoking, as recorded at the first ante-
natal visit, was retrieved from the MBR. Covariates were
categorised as shown in Table 1.
Outcomes The main outcome was pre-eclampsia, based on
ICD-10 codes (O140, O141, O149 and O15). Pre-eclampsia
was further divided into mild to moderate (ICD-10 codes
O140 and O149, respectively) and severe (ICD-10 codes
O141 and O15). Pre-eclampsia was also stratified by gesta-
tional age at delivery into preterm and term pre-eclampsia,
defined as a recorded pre-eclampsia diagnosis combined with
preterm or term delivery (at <37 weeks or ≥37 weeks, respec-
tively). There are several definitions of pre-eclampsia, and
classification may therefore vary between countries. In
Sweden, the clinical definition of pre-eclampsia was BP
≥140/90 mmHg (systolic/diastolic) combined with proteinuria
(at least 0.3 g per 24 h or a score of ≥1 on a urine dipstick on at
least two subsequent occasions) during the study period.
Severe pre-eclampsia is commonly defined as pre-eclampsia
with a systolic BP ≥160 mmHg, and/or a diastolic BP
≥110 mmHg and/or multiorgan involvement [23]. A
Swedish validation study found good agreement between reg-
istry information on pre-eclampsia diagnoses and information
in the individual records when using ICD-9 codes [24], and a
Danish study showed good validity for registry information on
pre-eclampsia when using ICD-10 codes [25].
Statistical analyses Rates of pre-eclampsia were calculated
separately for women without diabetes, women with type 1
diabetes and women with type 2 diabetes. We used logistic
regression analyses to estimate ORs and 95% CIs for pre-
eclampsia and subgroups of pre-eclampsia in women with
type 1 or type 2 diabetes. Women without diabetes were used
as the reference population. In the first adjusted model, ORs
were only adjusted for maternal BMI (model 1), while in the
second model ORs were additionally adjusted for maternal
parity, age, height, smoking, maternal country of birth and
education (model 2). To investigate whether the effect of
BMI on pre-eclampsia risk differed in women with and
2100 Diabetologia (2016) 59:2099–2105
without diabetes, we decided a priori to perform stratified
analyses of associations between BMI and pre-eclampsia risk
in women without diabetes, women with type 1 diabetes and
women with type 2 diabetes. Interactions were tested separate-
ly for women with type 1 and type 2 diabetes. Interaction
terms were introduced in the multivariate model (model 2),
and a p value of <0.05 for the interaction term was considered
statistically significant. For women with type 1 diabetes, anal-
yses were stratified by BMI category for all subtypes of pre-
eclampsia. Due to power concerns, it was not possible to
perform these analyses for women with type 2 diabetes. In
all analyses, the general estimation equation model was ap-
plied to account for repeated pregnancies.
Results
Rates of pre-eclampsia were higher in younger (≤24 years)
and nulliparous women, and increased with maternal BMI
(Table 1). A lower pre-eclampsia rate was observed in
smokers compared with non-smokers. Further, the rate of
pre-eclampsia was higher in Nordic women than in non-
Nordic women.
Compared with women without diabetes, the crude OR for
pre-eclampsia was more than six times higher in women with
type 1 diabetes and 3.5 times higher in women with type 2
diabetes. These risk estimates were reduced after adjustment
for maternal BMI, especially for women with type 2 diabetes
(Table 2, model 1). Further adjustment for other covariates
only slightly changed these risks (Table 2, model 2).
Type 1 and type 2 diabetes were both associated with in-
creased ORs for all subgroups of pre-eclampsia, and type 1
diabetes was consistently associated with higher risks com-
pared with type 2 diabetes (Table 3). Compared with women
without diabetes, the adjusted OR for severe pre-eclampsia
was almost six times higher in women with type 1 diabetes
and approximately 2.5 times higher in women with type 2
diabetes. The highest ORs were observed for pre-eclampsia
related to preterm birth. Compared with women without dia-
betes, the crude and adjusted ORs of pre-eclampsia with pre-
term birth were close to 11 times and nine times higher for
women with type 1 diabetes. In women with type 2 diabetes,
the OR for pre-eclampsia leading to preterm birth was reduced
from 4.74 (95% CI 3.13, 7.16) to 3.11 (95% CI 2.05, 4.70)
after adjustment for BMI (Table 3).
Data on BMI was available for 88.3% of women with type
1 diabetes, 90.6% of women with type 2 diabetes and 88.9%
of women in the reference population. In all, 0.4% of women
with type 1 diabetes were underweight, 47.9% were normal
weight, 33.6% were overweight and 18% were obese.
Corresponding figures for women with type 2 diabetes were:
underweight, 0.5%; normal weight, 16.9%; overweight,
27.7%; and obese, 54.7%. There were significant interactions
between maternal BMI and diabetes status with regard to pre-
eclampsia risk for both type 1 (p<0.001) and type 2 (p=0.01)
diabetes. We therefore performed stratified analyses of asso-
ciations between maternal BMI and pre-eclampsia in women
without diabetes, with type 1 diabetes, and with type 2 diabe-
tes. Especially in women without diabetes, but also in women
with type 1 diabetes, rates of pre-eclampsia increased with
maternal overweight and obesity (Table 4). The highest over-
all pre-eclampsia rate (18.6%) was seen in obese women with
type 1 diabetes. For those without diabetes, overweight and
Table 1 Maternal characteristics and rates of pre-eclampsia in women
with singleton births in Sweden between 1997 and 2012
Maternal characteristics Total (n) Pre-eclampsia
n %
Total 1,517,473 43,223 2.8
Maternal age (years)
≤ 24 227,953 7602 3.3
25–29 469,675 13,521 2.9
30–34 523,845 13,448 2.6
≥ 35 296,000 8652 2.9
Parity
Nulliparous 671,893 28,966 4.3
Parous 845,580 14,257 1.7
Early pregnancy BMI (kg/m2)
< 18.5 32,095 538 1.7
18.5–24.9 830,141 17,661 2.1
25.0–29.9 338,897 11,340 3.4
30.0–34.9 106,178 5533 5.2
≥ 35.0 42,046 3213 7.6
Data missing 168,116 4938 2.9
Maternal height (cm)
< 155 45,395 1429 3.2
155–164 499,906 15,094 3.0
165–174 737,640 20,348 2.8
≥ 175 142,284 3585 2.5
Data missing 92,248 2767 3.0
Daily smoking in early pregnancy
No 1,308,648 38,040 2.9
Yes 128,841 2714 2.1
Data missing 79,984 2469 3.1
Education (years)
9 376,896 10,714 2.8
10–11 394,385 12,604 3.2
12 210,515 5934 2.8
≥ 13 518,037 13,566 2.6
Data missing 17,640 405 2.3
Mother’s country of birth
Nordic 1,243,543 37,592 3.0
Non-Nordic 273,930 5631 2.0
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obese women had 1.7-fold and a more than threefold in-
creased odds of pre-eclampsia, respectively, compared with
normal weight women (Table 4). In women with type 2 dia-
betes, overweight and obesity were not associated with in-
creased risks of pre-eclampsia compared with normal weight.
Compared with normal weight women with type 1 diabetes,
obesity led to modest increments in the risk of all subtypes of
pre-eclampsia: the adjusted ORs for moderate pre-eclampsia,
severe pre-eclampsia and pre-eclampsia with preterm birth in
obese women with type 1 diabetes were 1.42 (95% CI 1.11,
1.82), 1.49 (95% CI 1.09, 2.05) and 1.33 (95% CI 0.97, 1.83),
respectively.
Discussion
To our knowledge, the present population-based cohort study is
the first to demonstrate the impact of maternal BMI in women
with type 1 and type 2 diabetes on the risk of pre-eclampsia,
including subtypes of pre-eclampsia. We found no evidence
that maternal overweight and obesity are associated with an
increased risk of pre-eclampsia in women with type 2 diabetes,
as opposed to women with type 1 diabetes and, especially,
women without diabetes. The observation that rates of pre-
eclampsia were increased in women with type 1 and type 2
diabetes is in accordance with previous reports. However, we
also found consistently higher rates of all subtypes of pre-
eclampsia in women with type 1 diabetes compared with wom-
en with type 2 diabetes. Rates of pre-eclampsia were also sig-
nificantly higher in Nordic than in non-Nordic women. This is
consistent with previous findings [26, 27].
Compared with women without diabetes, the ORs for pre-
eclampsia and subtypes of pre-eclampsia were substantially
increased in women with type 1 diabetes, and risk estimates
were only slightly attenuated after adjustment for BMI. This
demonstrates that the association between type 1 diabetes and
Table 2 Type 1 and type
2 diabetes and risks of
pre-eclampsia
Diabetic disease Total (n) Pre-eclampsia
n % Crude OR (95% CI) Adjusted OR (95% CI)
Model 1a Model 2b
No 1,509,525 42,034 2.8 1.00 1.00 1.00
Type 1 7062 1103 15.6 6.32 (5.88, 6.78) 5.74 (5.31, 6.20) 5.64 (5.19, 6.12)
Type 2 886 86 9.7 3.45 (2.71, 4.39) 2.11 (1.65, 2.70) 2.30 (1.67, 3.17)
a Adjusted for maternal BMI
bAdjusted for maternal BMI, height, age, parity, education, smoking and country of birth.
Table 3 Type 1 and type 2 diabetes and risks of pre-eclampsia subtypes
Pre-eclampsia subtype Diabetic disease Total (n) Pre-eclampsia
n % Crude OR (95% CI) Adjusted OR (95% CI)
Model 1a Model 2b
Mild/moderate No 1,509,525 28,460 1.9 1.00 1.00 1.00
Type 1 7062 704 10.0 5.69 (5.24, 6.19) 5.08 (4.65, 5.56) 4.89 (4.45, 5.38)
Type 2 886 58 6.5 3.44 (2.58, 4.58) 2.01 (1.50, 2.68) 2.18 (1.50, 3.16)
Severe No 1,509,525 13,574 0.9 1.00 1.00 1.00
Type 1 7062 399 5.6 6.51 (5.84, 7.25) 5.95 (5.29, 6.69) 5.75 (5.08, 6.52)
Type 2 886 28 3.2 3.50 (2.37, 5.16) 2.29 (1.53, 3.45) 2.45 (1.47, 4.07)
Preterm (<37 weeks) No 1,509,525 9360 0.6 1.00 1.00 1.00
Type 1 7062 435 6.2 10.35 (9.29, 11.52) 9.08 (8.06, 10.22) 8.72 (7.68, 9.89)
Type 2 886 27 3.1 4.74 (3.13, 7.16) 3.11 (2.05, 4.70) 3.22 (1.93, 5.37)
Term (Q37 weeks) No 1,509,525 32,674 2.2 1.00 1.00 1.00
Type 1 7062 668 9.5 4.65 (4.27, 5.06) 4.30 (3.93, 4.71) 4.19 (3.81, 4.62)
Type 2 886 59 6.7 3.06 (2.32, 4.03) 1.80 (1.36, 2.40) 1.96 (1.36, 2.82)
a Adjusted for maternal BMI (kg/m2 )
b Adjusted for maternal BMI, height, age, parity, education, smoking and country of birth
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pre-eclampsia is independent of BMI, even though the odds
for pre-eclampsia increased further with maternal overweight
and obesity. In contrast, in women with type 2 diabetes, the
risk of pre-eclampsia was partially confounded by BMI, while
increasing maternal BMI did not further increase the pre-
eclampsia risk. These discrepancies probably reflect differ-
ences in genetic factors and the clinical expression of both
type 1 and type 2 diabetes. In addition, the impact of BMI
on the risk of pre-eclampsia may vary with the duration of
diabetes, and the presence or absence of diabetes-related com-
plications and other risk factors for pre-eclampsia. The lack of
effect of BMI on the risk of pre-eclampsia in women with type
2 diabetes and the modestly increment in pre-eclampsia risk
conveyed by maternal obesity in women with type 1 diabetes
demonstrate that diabetes disease per se is a much stronger
risk factor for pre-eclampsia than BMI. This is also consistent
with comparable risks of cardiovascular death for normal
weight and overweight/obese adults with type 2 diabetes
[28]. However, the vast majority (83%) of women with type
2 diabetes in our study were either overweight or obese (BMI
≥25 kg/m2), and considerably fewer women with type 2 dia-
betes than with type 1 diabetes. Thus, it is possible that the
range of exposures was insufficient to demonstrate a signifi-
cant contribution of BMI on the risk of pre-eclampsia in wom-
en with type 2 diabetes or that a larger cohort was needed to
demonstrate an effect.
Studies comparing rates of pre-eclampsia in women with
type 1 diabetes and type 2 diabetes are scarce, and contradic-
tory results have been reported [29, 30]. In the present study,
rates of pre-eclampsia and subtypes of pre-eclampsia were
significantly higher in women with type 1 diabetes than in
women with type 2 diabetes. Differences in the rates of pre-
eclampsia in women with type 1 diabetes or type 2 diabetes
may be attributable to differences in risk factors, such as
chronic hypertension, level of glycaemic control, duration of
diabetes disease and diabetes microangiopathy. In addition,
comparison of placental findings in women with type 1 or
type 2 diabetes suggest that the strain of pregnancy may affect
maternal vascularisation differently in these two groups [31].
Diabetic nephropathy is a complication of around 2.5–5%
of pregnancies in womenwith diabetes [32, 33] and is a strong
risk factor for pre-eclampsia [34]. Interestingly, in women
with type 1 diabetes and nephropathy, maternal overweight
was the only additional factor associated with adverse preg-
nancy outcome, whereas duration of diabetes, level of
glycaemic control and weight gain in pregnancy did not influ-
ence risks [35]. Microalbuminuria, the forerunner to diabetic
nephropathy has also been associated with a fourfold in-
creased risk of pre-eclampsia in women with type 1 diabetes
[36]. There has been less investigation into the impact of dif-
ferent degrees of nephropathy on the risk of pre-eclampsia in
women with type 2 diabetes. However, a recent nationwide
study from Denmark demonstrated that women with type 2
diabetes and overt nephropathy or microalbuminuria had
comparable rates of pre-eclampsia to those of women with
type 1 diabetes and different degrees of diabetic nephropathy
[32]. Elevated HbA1c in early pregnancy is another important
risk factor for pre-eclampsia in womenwith type 1 diabetes [9,
37]. Obesity is associated with increased insulin resistance
and elevated glucose concentrations [38]. Against this back-
ground, one might speculate that the increment in risk of pre-
eclampsia in obese women with type 1 diabetes may reflect a
poorer glycaemic control compared with normal weight wom-
en with type 1 diabetes. Furthermore, the aetiology of pre-
eclampsia remains undefined. Pre-eclampsia includes abnor-
mal vascular development of the placenta and systemic ma-
ternal endothelial dysfunction [3]. Obesity and pre-eclampsia
share several features, including subclinical inflammation, in-
sulin resistance and lipotoxicity [39, 40]. Lipotoxicity is asso-
ciated withmaternal vascular dysfunction and reduced tropho-
blast invasion into the developing placenta; it has been pro-
posed to link maternal overweight and obesity to the risk of
pre-eclampsia [39]. It has also been hypothesised that mater-
nal obesity may increase the risk of pre-eclampsia by reducing
endogenous production of nitric oxide, with the subsequent
increased risk of endothelial dysfunction [41]. Adverse meta-
bolic and vascular effects of overweight and obesity are par-
ticularly seen in visceral obesity. Thus, it is possible that the
impact of maternal BMI on the risk of pre-eclampsia may
differ between women with different fat mass distributions.
Strengths of this study include the population-based de-
sign, including data on all pregnancies in women with type
Table 4 Risks of pre-eclampsia
stratified by maternal BMI in
women with and without diabetes
Diabetic disease BMI (kg/m2)
18.5–24.9 25–29.9 ≥30
% OR (95% CI)a % OR (95% CI) a % OR (95% CI) a
No 2.1 1.00 3.3 1.69 (1.64, 1.73) 5.8 3.22 (3.12, 3.32)
Type 1 14.2 1.00 16.1 1.17 (0.99, 1.38) 18.6 1.48 (1.20, 1.82)
Type 2 8.8 1.00 6.9 0.84 (0.33, 2.16) 11.5 1.23 (0.56, 2.72)
a Underweight women were excluded
bAdjusted for maternal BMI, height, age, parity, education, smoking and country of birth
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1 diabetes and type 2 diabetes in Sweden between 1997 and
2012. Data were prospectively collected within a healthcare
context, which largely excludes recall bias. The large study
cohort enabled us to investigate risks of pre-eclampsia and
subtypes of pre-eclampsia in women with type 1 diabetes
and type 2 diabetes, and also to investigate the importance
of BMI in stratified analyses. In Sweden, management of
pregnancies with pregestational diabetes is uniform and preg-
nancy outcomes do not differ with geographical area [1]. We
were able to adjust for important maternal diagnoses and con-
founders [18, 24, 25]. During the study period, the main
screening strategy for identifying gestational diabetes was re-
peated capillary random plasma glucose values of ≥9 mmol/l
or the presence of traditional risk factors (i.e. first-degree fam-
ily history of diabetes, obesity, history of gestational diabetes
or delivery of a large-for-date baby in a previous pregnancy).
Plasma glucose is also measured in cases of glucosuria. In
addition, an OGTT is usually also performed in cases of fetal
growth acceleration or polyhydramnios. A diagnosis of gesta-
tional diabetes was based on an OGTT (75 g glucose) per-
formed within a week for cases in which a random plasma
glucose value was above the limit. Women with traditional
risk factors are tested once or twice during the first 30 weeks
of gestation. A diagnosis of gestational diabetes mellitus was
based on a fasting plasma glucose value of ≥7 mmol/l and/or a
2 h plasma glucose value of ≥10 mmol/l. As almost all obese
women (BMI ≥30 kg/m2) are submitted to an OGTT during
antenatal care, it is unlikely that gestational diabetes was un-
detected in this group of women.
While we consider the risk of misclassification of type 1
diabetes to be negligible, we cannot exclude the possibility that
some misclassification of type 2 diabetes and gestational dia-
betes may have biased our results: women with type 2 diabetes
may have been misclassified as having gestational diabetes.
The SwedishMBR does not contain information onmaternal
glycaemic control, duration of diabetes or diabetes-associated
complications. In this study, we used BMI in early pregnancy
as a proxy for fat mass. The validity of this proxy measure is
supported by the strong association (r2=0.84) betweenBMI and
total fat mass in early pregnancy [42]. However, it is important
to remember that the impact of maternal BMI on the risk of pre-
eclampsia may differ with distribution of fat mass.
In conclusion, we found that maternal overweight and obe-
sity increase the risks of pre-eclampsia and subtypes of pre-
eclampsia in women with type 1 diabetes and, especially, in
women without diabetes. In contrast, maternal BMI did not
substantially influence the risk of pre-eclampsia in women
with type 2 diabetes. Our findings indicate that striving for a
normal pre-pregnancy BMI could reduce the risk of pre-
eclampsia in women with type 1 diabetes and women without
diabetes. Further, as maternal BMI is also related to other
pregnancy and obstetric complications, women with type 2
diabetes would probably benefit in other respects from having
a normal weight. Given the increasing prevalence of maternal
obesity and the severity of the preeclamptic disease, it is im-
portant that our results are confirmed in other populations.
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